Pfiz­er jumps in­to the heat­ed PhI­II race for new-wave JAK in­hibitors — but safe­ty frets loom large

Pfiz­er has racked up a pos­i­tive slate of Phase III da­ta for its an­ti-in­flam­ma­to­ry JAK1 in­hibitor abroc­i­tinib (PF-04965842), which the phar­ma gi­ant is hop­ing to steer to the FDA rel­a­tive­ly soon as it looks to get in­to a heat­ed block­buster race that’s been heav­i­ly over­shad­owed by new safe­ty warn­ings for the class.

All we’re get­ting now are some un­spec­i­fied — though promis­ing — re­sults, with the phar­ma gi­ant lay­ing claim to a sta­tis­ti­cal­ly sig­nif­i­cant re­sult against a place­bo for atopic der­mati­tis. Pfiz­er, though, wants to go up against some deeply en­trenched ri­vals in a high­ly com­pet­i­tive field, and there’s no re­al in­sight to of­fer on how that stacks up. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.